"The real-world benefit of novel androgen receptor-targeting agents (ARTA) before and after docetaxel in CRPC with bone metastases in Japan: A subanalysis of the PROSTAT-BSI, a prospective observational study before and after approval of novel ARTAs."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

The real-world benefit of novel androgen receptor-targeting agents (ARTA) before and after docetaxel in CRPC with bone metastases in Japan: A subanalysis of the PROSTAT-BSI, a prospective observational study before and after approval of novel ARTAs.

43Background: ARTAs (enzalutamide and abiraterone) have been approved for relapse of prostate cancer in Japan since 2014. However, the efficacy of ARTAs for overall survival (OS) has not yet been… Click to show full abstract

Keywords: receptor targeting; world benefit; benefit novel; novel androgen; androgen receptor; real world

Journal Title: Journal of Clinical Oncology
Year Published: 2021

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended